Which has higher valuation & earnings, AVBP or TENX?

ArriVent BioPharma is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ArriVent BioPharma N/A N/A -$166.31M -$3.47 N/A Tenax Therapeutics N/A N/A -$52.60M -$1.40 N/A

Is AVBP or TENX more profitable?

ArriVent BioPharma's return on equity of -48.98% beat Tenax Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets ArriVent BioPharma N/A -48.98% -45.44% Tenax Therapeutics N/A -56.32% -53.12%

Which has higher valuation & earnings, TENX or COAG?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tenax Therapeutics N/A N/A -$52.60M -$1.40 N/A Hemab Therapeutics N/A N/A N/A N/A N/A

Is TENX or COAG more profitable?

Hemab Therapeutics' return on equity of 0.00% beat Tenax Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tenax Therapeutics N/A -56.32% -53.12% Hemab Therapeutics N/A N/A N/A

Tenax Therapeutics (TENX) Competitors

$10.77 -0.18 (-1.64%)

Closing price 04:00 PM Eastern

Extended Trading

$10.79 +0.02 (+0.19%)

As of 06:07 PM Eastern

Compare

TENX vs. SEPN, AVBP, COAG, HROW, and WVE

Should you buy Tenax Therapeutics stock or one of its competitors? MarketBeat compares Tenax Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tenax Therapeutics include Septerna (SEPN), ArriVent BioPharma (AVBP), Hemab Therapeutics (COAG), Harrow (HROW), and WAVE Life Sciences (WVE). These companies are all part of the "pharmaceutical products" industry.

How does Tenax Therapeutics compare to Septerna?

Septerna (NASDAQ:SEPN) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

Septerna has a beta of 2.39, suggesting that its share price is 139% more volatile than the broader market. Comparatively, Tenax Therapeutics has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market.

Septerna has higher revenue and earnings than Tenax Therapeutics. Septerna is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Septerna	$45.95M	29.97	-$48.88M	-$0.81	N/A
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.40	N/A

In the previous week, Septerna had 3 more articles in the media than Tenax Therapeutics. MarketBeat recorded 4 mentions for Septerna and 1 mentions for Tenax Therapeutics. Tenax Therapeutics' average media sentiment score of 1.87 beat Septerna's score of 0.55 indicating that Tenax Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Septerna	Positive
Tenax Therapeutics	Very Positive

Tenax Therapeutics has a net margin of 0.00% compared to Septerna's net margin of -49.88%. Septerna's return on equity of -12.72% beat Tenax Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Septerna	-49.88%	-12.72%	-8.87%
Tenax Therapeutics	N/A	-56.32%	-53.12%

Septerna currently has a consensus price target of $43.13, suggesting a potential upside of 41.16%. Tenax Therapeutics has a consensus price target of $29.67, suggesting a potential upside of 175.46%. Given Tenax Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tenax Therapeutics is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Septerna	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Tenax Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

1.7% of Tenax Therapeutics shares are held by institutional investors. 4.3% of Septerna shares are held by insiders. Comparatively, 3.1% of Tenax Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Septerna beats Tenax Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Tenax Therapeutics compare to ArriVent BioPharma?

ArriVent BioPharma (NASDAQ:AVBP) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation and earnings.

In the previous week, ArriVent BioPharma and ArriVent BioPharma both had 1 articles in the media. ArriVent BioPharma's average media sentiment score of 1.87 equaled Tenax Therapeutics'average media sentiment score.

Company	Overall Sentiment
ArriVent BioPharma	Very Positive
Tenax Therapeutics	Very Positive

ArriVent BioPharma is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.40	N/A

9.5% of ArriVent BioPharma shares are owned by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are owned by institutional investors. 8.6% of ArriVent BioPharma shares are owned by company insiders. Comparatively, 3.1% of Tenax Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

ArriVent BioPharma currently has a consensus price target of $43.38, suggesting a potential upside of 45.65%. Tenax Therapeutics has a consensus price target of $29.67, suggesting a potential upside of 175.46%. Given Tenax Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Tenax Therapeutics is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Tenax Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

ArriVent BioPharma has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market. Comparatively, Tenax Therapeutics has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market.

ArriVent BioPharma's return on equity of -48.98% beat Tenax Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ArriVent BioPharma	N/A	-48.98%	-45.44%
Tenax Therapeutics	N/A	-56.32%	-53.12%

Summary

ArriVent BioPharma beats Tenax Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Tenax Therapeutics compare to Hemab Therapeutics?

Tenax Therapeutics (NASDAQ:TENX) and Hemab Therapeutics (NASDAQ:COAG) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.40	N/A
Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A

Tenax Therapeutics currently has a consensus price target of $29.67, suggesting a potential upside of 175.46%. Hemab Therapeutics has a consensus price target of $41.75, suggesting a potential upside of 59.53%. Given Tenax Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Tenax Therapeutics is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenax Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Hemab Therapeutics	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Hemab Therapeutics' return on equity of 0.00% beat Tenax Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenax Therapeutics	N/A	-56.32%	-53.12%
Hemab Therapeutics	N/A	N/A	N/A

1.7% of Tenax Therapeutics shares are held by institutional investors. 3.1% of Tenax Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Hemab Therapeutics had 4 more articles in the media than Tenax Therapeutics. MarketBeat recorded 5 mentions for Hemab Therapeutics and 1 mentions for Tenax Therapeutics. Tenax Therapeutics' average media sentiment score of 1.87 beat Hemab Therapeutics' score of 0.61 indicating that Tenax Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Tenax Therapeutics	Very Positive
Hemab Therapeutics	Positive

Summary

Tenax Therapeutics beats Hemab Therapeutics on 6 of the 9 factors compared between the two stocks.

How does Tenax Therapeutics compare to Harrow?

Tenax Therapeutics (NASDAQ:TENX) and Harrow (NASDAQ:HROW) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

1.7% of Tenax Therapeutics shares are owned by institutional investors. Comparatively, 72.8% of Harrow shares are owned by institutional investors. 3.1% of Tenax Therapeutics shares are owned by company insiders. Comparatively, 12.8% of Harrow shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Tenax Therapeutics currently has a consensus target price of $29.67, suggesting a potential upside of 175.46%. Harrow has a consensus target price of $69.43, suggesting a potential upside of 108.37%. Given Tenax Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Tenax Therapeutics is more favorable than Harrow.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenax Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Harrow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Harrow has higher revenue and earnings than Tenax Therapeutics. Harrow is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.40	N/A
Harrow	$272.30M	4.56	-$5.14M	-$0.41	N/A

In the previous week, Harrow had 3 more articles in the media than Tenax Therapeutics. MarketBeat recorded 4 mentions for Harrow and 1 mentions for Tenax Therapeutics. Tenax Therapeutics' average media sentiment score of 1.87 beat Harrow's score of 0.81 indicating that Tenax Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Tenax Therapeutics	Very Positive
Harrow	Positive

Tenax Therapeutics has a net margin of 0.00% compared to Harrow's net margin of -5.57%. Harrow's return on equity of 19.59% beat Tenax Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenax Therapeutics	N/A	-56.32%	-53.12%
Harrow	-5.57%	19.59%	2.26%

Tenax Therapeutics has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market. Comparatively, Harrow has a beta of 0.28, indicating that its share price is 72% less volatile than the broader market.

Summary

Harrow beats Tenax Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Tenax Therapeutics compare to WAVE Life Sciences?

Tenax Therapeutics (NASDAQ:TENX) and WAVE Life Sciences (NASDAQ:WVE) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

Tenax Therapeutics has higher earnings, but lower revenue than WAVE Life Sciences. Tenax Therapeutics is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.40	N/A
WAVE Life Sciences	$42.73M	25.94	-$204.38M	-$1.06	N/A

1.7% of Tenax Therapeutics shares are owned by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are owned by institutional investors. 3.1% of Tenax Therapeutics shares are owned by company insiders. Comparatively, 24.3% of WAVE Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Tenax Therapeutics has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.33, indicating that its stock price is 233% less volatile than the broader market.

Tenax Therapeutics has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -255.70%. Tenax Therapeutics' return on equity of -56.32% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenax Therapeutics	N/A	-56.32%	-53.12%
WAVE Life Sciences	-255.70%	-56.76%	-42.80%

In the previous week, WAVE Life Sciences had 4 more articles in the media than Tenax Therapeutics. MarketBeat recorded 5 mentions for WAVE Life Sciences and 1 mentions for Tenax Therapeutics. Tenax Therapeutics' average media sentiment score of 1.87 beat WAVE Life Sciences' score of 0.32 indicating that Tenax Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Tenax Therapeutics	Very Positive
WAVE Life Sciences	Neutral

Tenax Therapeutics currently has a consensus price target of $29.67, indicating a potential upside of 175.46%. WAVE Life Sciences has a consensus price target of $27.25, indicating a potential upside of 373.09%. Given WAVE Life Sciences' stronger consensus rating and higher probable upside, analysts plainly believe WAVE Life Sciences is more favorable than Tenax Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenax Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87

Summary

WAVE Life Sciences beats Tenax Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Tenax Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TENX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TENX vs. The Competition

Export

Metric	Tenax Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$290.45M	$3.24B	$6.47B	$12.54B
Dividend Yield	N/A	2.38%	2.69%	5.22%
P/E Ratio	-7.69	9.91	18.89	22.53
Price / Sales	N/A	315.63	520.79	112.26
Price / Cash	N/A	111.64	41.34	57.13
Price / Book	1.03	6.63	9.84	6.72
Net Income	-$52.60M	$24.20M	$3.57B	$337.19M
7 Day Performance	-9.34%	-3.24%	-1.16%	0.48%
1 Month Performance	-15.73%	0.53%	3.85%	5.07%
1 Year Performance	82.85%	47.24%	27.40%	34.25%

Tenax Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TENX Tenax Therapeutics	3.705 of 5 stars	$10.77 -1.6%	$29.67 +175.5%	+80.1%	$290.45M	N/A	N/A	9	Positive News Analyst Forecast
SEPN Septerna	2.3312 of 5 stars	$30.65 +8.1%	$43.13 +40.7%	+201.5%	$1.28B	$45.95M	N/A	N/A
AVBP ArriVent BioPharma	2.5007 of 5 stars	$27.94 +4.5%	$43.13 +54.3%	+36.0%	$1.24B	N/A	N/A	40
COAG Hemab Therapeutics	4.8047 of 5 stars	$27.84 +7.5%	$41.75 +50.0%	N/A	$1.23B	N/A	N/A	72	News Coverage Short Interest Increase Gap Up
HROW Harrow	4.45 of 5 stars	$34.17 +3.5%	$69.43 +103.2%	+9.6%	$1.23B	$272.30M	N/A	180

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TENX) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tenax Therapeutics (TENX) Competitors

TENX vs. SEPN, AVBP, COAG, HROW, and WVE

How does Tenax Therapeutics compare to Septerna?

Summary

How does Tenax Therapeutics compare to ArriVent BioPharma?

Summary

How does Tenax Therapeutics compare to Hemab Therapeutics?

Summary

How does Tenax Therapeutics compare to Harrow?

Summary

How does Tenax Therapeutics compare to WAVE Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TENX vs. The Competition

Tenax Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tenax Therapeutics (TENX) Competitors

TENX vs. SEPN, AVBP, COAG, HROW, and WVE

How does Tenax Therapeutics compare to Septerna?

Which has more volatility & risk, SEPN or TENX?

Which has preferable earnings & valuation, SEPN or TENX?

Does the media favor SEPN or TENX?

Is SEPN or TENX more profitable?

Do analysts prefer SEPN or TENX?

Do institutionals & insiders have more ownership in SEPN or TENX?

Summary

How does Tenax Therapeutics compare to ArriVent BioPharma?

Does the media refer more to AVBP or TENX?

Which has higher valuation & earnings, AVBP or TENX?

Do institutionals & insiders have more ownership in AVBP or TENX?

Do analysts prefer AVBP or TENX?

Which has more volatility & risk, AVBP or TENX?

Is AVBP or TENX more profitable?

Summary

How does Tenax Therapeutics compare to Hemab Therapeutics?

Which has higher valuation & earnings, TENX or COAG?

Do analysts prefer TENX or COAG?

Is TENX or COAG more profitable?

Do institutionals & insiders hold more shares of TENX or COAG?

Does the media prefer TENX or COAG?

Summary

How does Tenax Therapeutics compare to Harrow?

Do insiders & institutionals hold more shares of TENX or HROW?

Do analysts recommend TENX or HROW?

Which has higher earnings & valuation, TENX or HROW?

Does the media prefer TENX or HROW?

Is TENX or HROW more profitable?

Which has more risk and volatility, TENX or HROW?

Summary

How does Tenax Therapeutics compare to WAVE Life Sciences?

Which has higher valuation and earnings, TENX or WVE?

Do insiders & institutionals have more ownership in TENX or WVE?

Which has more volatility and risk, TENX or WVE?

Is TENX or WVE more profitable?

Does the media favor TENX or WVE?

Do analysts recommend TENX or WVE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TENX vs. The Competition

Tenax Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools